Noel Kurdi joined Apogee in July 2023 as VP of Investor Relations and brings over 18 years of experience in investor relations, capital markets and strategy. Prior to Apogee, Noel served as VP of Investor Relations and Communications at Prometheus Biosciences, spanning from pre-IPO in 2021 to its 2023 acquisition by Merck & Co for $10.8 billion. Noel held multiple Investor Relations roles in-house and externally at Trout Group/Trout Capital, an investor relations, broker-dealer, and strategic advisory firm dedicated to the biotech industry. She began her career as a capital markets analyst at AIG Investments and has held various roles in investor relations, equity research and sales & trading. Noel graduated with a BBA in Finance and Marketing from George Washington University and an MBA in Finance from Fordham University. She enjoys running, surfing, art collecting, and moonlighting as her daughters’ in-house DJ and dance choreographer.